ODAC Votes Against Safety Profile of Secura Bio’s P13K Inhibitor

Default sub title

minute read

Written by Biospace on September 26, 2022

In an 8-4 vote, the FDA’s Oncologic Drugs Advisory Committee Roster voted against the benefit-risk profile of Secura Bio’s P13K inhibitor Copiktra.

Topics: Press Coverage

Comments